Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology $(ASH)$ Annual Meeting
Initial Results from BEACON Phase 1/2 Clinical Trial Demonstrate Potential for Differentiation of Base Editing and BEAM-101
Preclinical ESCAPE Data Establish Proof-of-concept for Non-genotoxic, Antibody-based Conditioning and Engraftment in Non-human Primates
Clinical Data from Phase 1/2 BEAM-201 Trial Demonstrate Therapeutic Potential of First Quadruplex-edited Allogeneic CAR-T Cell Therapy
Beam to Host Investor Event on Dec. 8, 2024, at 8 p.m. PT
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the acceptance of multiple oral and poster presentations, including the first clinical data from a Beam program, at the 66th American Society of Hematology $(ASH.AU)$ Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego.
"For people living with severe sickle cell disease, a serious medical condition with reduced life expectancy, stem cell transplant with genotoxic chemotherapy is the only currently available curative option. At Beam, we have a long-term commitment to delivering better treatments for these patients, first with BEAM-101 as a potentially superior autologous cell product, followed by ESCAPE, which seeks to eliminate chemotherapy from the transplant process altogether," said John Evans, chief executive officer of Beam. "Today represents an important milestone toward this vision as we unveil data with our base editing technology across both approaches to treating sickle cell disease. The initial results for BEAM-101 provide emerging clinical validation of base editing and of our preclinical hypothesis that more precise and efficient editing, without double-stranded DNA breaks, can lead to a differentiated product profile, with greater and more uniform induction of fetal hemoglobin, deeper reduction of sickle hemoglobin, and potentially faster engraftment."
"Our proof-of-concept data for ESCAPE in non-human primates demonstrate that base editing could enable antibody conditioning and engraftment for stem cell transplant without chemotherapy, a potential breakthrough in the field of hematology and for patients," said Giuseppe Ciaramella, Ph.D., president of Beam. "Along with the strong translation from preclinical to clinical of our BEAM-101 program, these data reflect the potential of base editing to enable new therapeutic possibilities for people suffering from serious diseases."
BEAM-101 Oral and Poster Presentations
Title: Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
Abstract: 513
Oral Session: 801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside
Presentation Time: Sunday, Dec. 8, 2024, at 10 a.m. PT
Location: San Diego Convention Center, Room 30
Presenter: Matthew M. Heeney, M.D., Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Key Highlights:
-- Preliminary data as of a July 2, 2024, data cut from BEACON, a Phase 1/2
single-arm, open-label clinical trial evaluating the safety and efficacy
of a single dose of BEAM-101 in patients with sickle cell disease $(SCD)$
with severe vaso-occlusive crises (VOCs).
-- Initial safety profile was consistent with busulfan conditioning and
autologous hematopoietic stem cell transplantation $(HSCT)$.
-- In all patients dosed (n=6), there were no >=Grade 3 adverse
events (AEs) or serious AEs related to treatment with BEAM-101.
-- One patient died four months after BEAM-101 infusion due to
respiratory failure that was determined by the investigator to be
likely related to busulfan conditioning and deemed unrelated to
BEAM-101. The case was reviewed by the Data Safety Monitoring
Committee and the U.S. Food and Drug Administration. Pulmonary
complications are a known cause of morbidity and, in rare cases,
mortality in patients undergoing myeloablation with chemotherapy,
such as busulfan, and stem cell transplantation.
-- All patients dosed achieved their target cell dose with either 1 or 2
mobilization cycles (mean: 1.5).
-- All 4 patients with >=1 month of follow-up achieved neutrophil and
platelet engraftment at a median of 17 (15--19) and 20 (11--34) days,
respectively.
-- All 4 patients experienced rapid and robust fetal hemoglobin (HbF)
induction by Month 1 (>60%) and corresponding sickle hemoglobin (HbS)
reduction (<=36%) in non-transfused blood, which was sustained over time.
-- Markers of hemolysis normalized or improved for all 4 patients.
-- No VOCs were reported by investigators post-treatment.
-- These data support base editing of the HBG1/2 promoters as a therapeutic
modality for the treatment of SCD and the ongoing development of
BEAM-101.
-- The presentation at ASH will include additional data with more patients
and longer follow-up.
Title: Impact of BEAM-101 Treatment on Red Blood Cell Hemoglobin Expression, Rheology and Sickling Properties: Initial data from the BEACON Phase 1/2 study of Autologous CD34+ Base Edited Hematopoietic Stem Cells in Sickle Cell Disease
Abstract: 4957
Poster Session: 801. Gene Therapies: Poster III
Session Time: Monday, Dec. 9, 2024, from 6-8 p.m. PT
Location: San Diego Convention Center, Halls G-H
Presenter: Priya S. Chockalingam, Ph.D., Beam Therapeutics
Key Highlights:
-- Preliminary data as of a July 2, 2024, data cut includes exploratory
biomarker assessments of red blood cell (RBC) hemoglobin expression,
health and function in 3 patients for two or more of the following
visits: screening, Month 1, 2, 3 and 6.
-- Initial results demonstrated 98-99% of RBCs expressing HbF as early as
Month 1, with near complete elimination of RBCs expressing solely HbS
post-treatment with BEAM-101.
-- The data showed reduction in RBC sickling, comparable to sickle cell
trait, reduced cell adhesion and improved hemorheological properties of
blood post-treatment with BEAM-101.
-- The presentation at ASH will include additional data with more patients
and longer follow-up.
ESCAPE Oral Presentation:
Title: CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model
Abstract: 516
Oral Session: 801. Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside
Presentation Time: Sunday, Dec. 8, 2024, at 10:45 a.m. PT
Location: San Diego Convention Center, Room 30
Presenter: Selami Demirci, Ph.D., National Institutes of Health
Key Highlights:
-- Study investigated whether Beam's Engineered Stem Cell Antibody Evasion
(ESCAPE) approach, using CD117 monoclonal antibody (mAb) conditioning,
could successfully achieve long-term engraftment and induce robust levels
of HbF in an immunocompetent host. Researchers used a non-human primate
(NHP) model where autologous CD34+ hematopoietic stem and progenitor
cells were multiplex edited to target a single epitope on CD117 and the
promoter regions of HBG1/2, allowing cells to avoid detection by the
conditioning mAb while upregulating HbF.
-- Two NHPs were conditioned with different doses (10 mg/kg and 25 mg/kg) of
CD117 mAb, instead of busulfan, 7 days prior to transplantation.
Post-transplant, further mAb treatments were administered to maintain
competitive advantage for the edited cells.
-- mAb-based conditioning was well tolerated, with no need for NHP
supportive care.
-- Both NHPs showed rapid and significant induction of HbF. The percentage
of red blood cells expressing HbF (F-cells) reached 61% as early as 8
weeks post-transplant in one NHP and stabilized at 85% by 35 weeks in
both animals. Concurrently, levels of HbF increased rapidly, reaching
55% at 35 weeks post-transplant in both animals.
-- Data suggest that ESCAPE, combined with CD117 mAb conditioning and
selection, can achieve long-term engraftment and induce high levels of
HbF, offering a promising alternative to traditional genotoxic
conditioning in autologous HSCT.
-- The presentation at ASH will include additional data.
BEAM-201 Poster Presentation:
Title: BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti CD7 CAR-T-Cells
Abstract: 4838
Poster Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Session Time: Monday, Dec. 9, 2024, from 6-8 p.m. PT
Location: San Diego Convention Center, Halls G-H
Presenter: Caroline Diorio, M.D., FRCPC, FAAP, Children's Hospital of Philadelphia
(MORE TO FOLLOW) Dow Jones Newswires
November 05, 2024 09:00 ET (14:00 GMT)
Comments